Page last updated: 2024-08-26

yttrium radioisotopes and Neuroendocrine Tumors

yttrium radioisotopes has been researched along with Neuroendocrine Tumors in 137 studies

Research

Studies (137)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	7 (5.11)	18.2507
2000's	29 (21.17)	29.6817
2010's	79 (57.66)	24.3611
2020's	22 (16.06)	2.80

Authors

Authors	Studies
Barentsz, MW; Braat, AJAT; Braat, MNGJA; Ebbers, SC; Lam, MGEH; van Roekel, C	1
Bober, B; Brodowska-Kania, D; Kaminski, G; Kapusta, W; Kolodziej, M; Lubas, A; Saracyn, M	1
Brown, DB; Collins, ZS; Gandhi, RT; Kennedy, AS; Matsuoka, L; O'Hara, R; Sze, DY; Vaheesan, K; Wang, EA; Wong, TY; Zhang, KS	1
Geramifar, P; Ghorbani, R; Miller, C; Peer-Firozjaei, M; Rahmim, A; Tajik-Mansoury, MA; Zarifi, S	1
Al Maraih, I; Hubalewska-Dydejczyk, A; Kania-Kuc, A; Morawiec-Sławek, K; Opalińska, M; Sowa-Staszczak, A	1
Bober, B; Durma, AD; Kamiński, G; Kapusta, W; Kołodziej, M; Lubas, A; Niemczyk, S; Saracyn, M	1
Ambrosini, V; Bonazzi, N; Fanti, S; Fortunati, E; Zanoni, L	1
Baum, RP; Chen, X; Kulkarni, HR; Liu, Q; Schuchardt, C; Zhang, J; Zhao, T; Zhu, Z	1
Armstrong, E; Cloyd, JM; Dillhoff, M; Egger, ME; Konda, B; Martin, RC; Pawlik, TM; Philips, P; Scoggins, CR; Shah, M	1
Bilha, SC; Constantin, V; Covic, A; Matovic, M; Nistor, I; Simona, V; Stefanescu, C; Stolniceanu, CR	1
Bagni, O; Cianni, R; Filippi, L; Schillaci, O	1
Brennan, VK; Paprottka, PM; Peters, R; Pollock, RF	1
Başaran, M; Büyükkaya, F; Engin, MN; Kovan, B; Özkan, ZG; Poyanli, A; Sağlam, S; Türkmen, C; Yilmaz, E	1
Baum, RP; Hommann, M; Hörsch, D; Kaemmerer, D; Kulkarni, HR; Sehner, S; Twrznik, M	1
Davies, JM; Gill, S; Ho, S; Kennecke, HF; Lim, HJ; Liu, D; Loree, JM; Renouf, DJ; Tsang, ES	1
Clift, AK; Frilling, A	1
Bongiovanni, A; Cittanti, C; Di Iorio, V; Di Mauro, F; Ferrara, M; Ibrahim, T; Lolli, I; Mezzenga, E; Nicolini, S; Paganelli, G; Sansovini, M; Scarpi, E; Severi, S; Tardelli, E; Zovato, S	1
Baum, RP; Kulkarni, HR; Zhang, J	1
Benson, AB; Gabr, A; Gates, VL; Lewandowski, RJ; Mackey, RV; Miller, FH; Riaz, A; Salem, R; Su, YK; Yaghmai, V	1
Chapiro, J; Do Minh, D; Gebauer, B; Geschwind, JF; Gorodetski, B; Huang, Q; Lin, M; Liu, C; Savic, LJ; Schlachter, T; Smolka, S; Wainstejn, D	1
Adachi, A; Chansanti, O; Farsad, K; Geeratikun, Y; Jahangiri, Y; Kaufman, JA; Kolbeck, KJ; Matsui, Y; Stevens, JS	1
Alenezi, SA; Dannoon, SF; Elgazzar, AH	1
Andersson, M; Elf, AK; Henrikson, O; Jalnefjord, O; Johanson, V; Ljungberg, M; Svensson, J; Wängberg, B	1
Farsad, K; Jahangiri, Y; Kaufman, JA; Kolbeck, KJ; Pathak, P; Schenning, RC; Tomozawa, Y	1
Ćwikła, JB; Kolasińska-Ćwikła, A; Maciejkiewicz, KM; Łowczak, A	1
Cengel, KA; Damjanov, N; Metz, DC; Soulen, MC; Teitelbaum, UR; van Houten, D	1
Jeremic, MZ; Krstic, DZ; Matovic, MD; Nikezic, DR; Pantovic, SB	1
Bargellini, I; Crocetti, L; Fornaro, L; Lorenzoni, G; Vivaldi, C	1
Padia, SA	2
Cosgrove, DP; Ellsworth, S; Fan, KY; Garg, T; Geschwind, JF; Hacker-Prietz, A; Halappa, VG; Herman, JM; Hong, KK; Kamel, IR; Kumar, R; Pawlik, TM; Rosati, LM; Su, Z; Wild, AT; Ziegler, M	1
Frey, G; Jia, Z; McKinney, JM; Paz-Fumagalli, R; Sella, DM; Wang, W	1
Braat, AJAT; Kim, HS; Kloeckner, R; Lahner, H; Lohoefer, F; Nie, J; Schaarschmidt, BM; Steinle, V; Theysohn, J; Weber, M; Wildgruber, M	1
Brown, DB; El-Haddad, G; Lewandowski, RJ; Padia, SA; Toskich, BB	1
Ahmadzadehfar, H; Braat, AJAT; Brown, DB; Deroose, CM; Flamen, P; Frilling, A; Kappadath, SC; Lam, MGEH; Mahvash, A; Stothers, CL; Sze, DY	2
Al-Nahhas, A; Alsafi, A; Braat, AJAT; Clift, AK; Drymousis, P; Frilling, A; Habib, N; Tait, PN; Thomas, R; Wasan, HS	1
Colquhoun, SD; Friedman, ML; Kim, AS; Nissen, NN; Ozao-Choy, J; Wachsman, A; Wolin, EM; Yu, R	1
Hubalewska-Dydejczyk, A; Królicki, L; Kunikowska, J; Mikołajczak, R; Pawlak, D; Sowa-Staszczak, A	1
Banks, M; Cuthbertson, DJ; Gilbert, TM; Maltby, P; McKane, G; Palmer, DH; Poston, G; Pritchard, DM; Vinjamuri, S; Vora, J; Weissman, H	1
Bergsma, H; de Herder, WW; Kam, BL; Krenning, EP; Kwekkeboom, DJ; Peeters, RP; Teunissen, JJ; van Vliet, EI	1
Cacciari, G; Campana, D; Capurso, G; Delle Fave, G; Falconi, M; Nori, F; Panzuto, F; Partelli, S; Tamburrino, D; Tomassetti, P	1
Koopman, M; Lam, MG; Nijsen, JF; Rosenbaum, CE; Smits, ML; van den Bosch, MA; van den Hoven, AF; Zonnenberg, BA	1
Aksamit, D; Bajera, A; Czwarnowski, P; Królicki, L; Kunikowska, J; Pawlak, D; Pawłowicz, B; Sawicka, M	1
Li, H; Tang, K; Wang, L; Wen, Z; Zhang, H; Zhang, Q	1
Auernhammer, CJ; Ceelen, F; D'Anastasi, M; de Albéniz, XG; Haug, AR; Paprottka, PM; Reiser, MF; Rist, C; Sommer, WH; Theisen, D	1
Bergsland, EK; Fidelman, N; Hawkins, RA; Kelley, RK; Kerlan, RK; Ko, AH; Kohi, MP; Kolli, KP; Korn, WM; Luan, J; McWhirter, RM; Taylor, AG; Venook, AP	1
Baete, K; Bogaerts, K; Clement, PM; Deroose, CM; Haustermans, K; Koole, M; Mortelmans, L; Mottaghy, FM; Terwinghe, C; Van Binnebeek, S; Van Cutsem, E; Vanbilloen, B; Verbruggen, A; Verslype, C	1
Bauman, M; Kikolski, SG; Morshedi, MM; Rose, SC	1
Banerjee, A; Braat, AJ; Devcic, Z; Lam, MG; Rosenberg, J; Sze, DY; Techasith, T	1
Baum, RP; Blaickner, M	1
John, PK; Saif, MW	1
Allen-Auerbach, MS; Bluemel, C; Herrmann, K; Higuchi, T; Werner, RA	1
Arbizu, J; Domínguez-Prado, I; Elosúa, C; García-Velloso, MJ; Martí-Climent, JM; Peñuelas, I; Prieto, E; Richter, JA; Rodríguez-Fraile, M; Vigil, C	1
Baum, RP; Bodei, L; Cremonesi, M; Drozdov, I; Grana, CM; Kidd, M; Krenning, EP; Kwekkeboom, DJ; Lepensky, C; Modlin, IM; Paganelli, G	1
Akhurst, T; Heriot, AG; Lynch, AC; Michael, M; Ryan, J	1
Hicks, RJ	1
Bartenstein, P; Fendler, WP; Goritschan, A; Hacker, M; Haug, AR; Ilhan, H; Jakobs, TF; Paprottka, P	1
Agostini, M; Amadori, S; Bartolini, N; Bartolomei, M; Casi, M; De Lauro, F; Fabbri, C; Gentili, G; Mattone, V; Sarti, G	1
Abdülrezzak, Ü; Buyukkaya, F; Karaca, H; Kula, M; Tutuş, A	1
Camacho, JC; Kim, HS; Kokabi, N; Lahti, S; Schuster, DM; Xing, M	1
Bodei, L; Botta, F; Cremonesi, M; D'Errico, V; Ferrari, M; Fioroni, F; Grassi, E; Guerriero, F; Orecchia, R; Paganelli, G; Sarnelli, A; Strigari, L	1
Beer, AJ; Glatting, G; Kletting, P; Kull, T; Luster, M; Maaß, C; Malik, N	1
Ambinder, EM; Ghodadra, A; Kim, HS; Ludwig, JM; Prajapati, HJ; Xing, M	1
Bodei, L; Chiti, A; Cremonesi, M; Ezziddin, S; Forrer, F; Hicks, RJ; Kidd, M; Luster, M; Modlin, IM	1
Ardill, JE; Eatock, M; Johnston, BT; McCance, DR	1
Cramer, B; Kim, HS; Xing, M	1
Bartlett, DL; Chung, MH; Doherty, MG; Marsh, JW; Varma, MK; Wright, GP	1
Chao, C; Dagli, M; Mondschein, JI; Nadolski, G; Soulen, MC; Stavropoulos, SW; Sudheendra, D	1
Benson, AB; Hansen, PD; Kennedy, AS; Lewandowski, RJ; Liu, DM; Mulcahy, MF; Omary, RA; Rhee, TK; Salem, R; Takahashi, G	1
Hoffman, MA; Nowakowski, FS; Rubin, JI; Vinceguerra, VP; Warner, RR	1
Glenn, DM; Janssen, J; King, J; Liaw, W; Morris, DL; Quinn, R; Tong, D	1
Arnold, R; Dressler, M; El-Sheik, M; Gress, TM; Höffken, H; Kalinowski, M; Klose, KJ; König, A; Rinke, A; Wagner, HJ	1
Arveschoug, AK; Hjorthaug, K; Højgaard, L; Mortensen, J; Oturai, PS; Rehling, M	1
Choi, J; Kvols, LK; Strosberg, J; Turaga, KK	1
Roche, A	1
de Herder, WW; de Jong, M; Kam, BL; Krenning, EP; Kwekkeboom, DJ; Teunissen, JJ; Valkema, R; van Eijck, CH; van Essen, M	1
Bester, L; Cao, CQ; Liauw, W; Morris, DL; Yan, TD	1
Bodei, L; Paganelli, G; Pepe, G	1
de Herder, WW; Krenning, EP; Kwekkeboom, DJ	1
Forrer, F; Giovacchini, G; Müller-Brand, J; Nicolas, G	1
Dabasi, G; Igaz, P; Kender, Z; Rácz, K; Reismann, P; Sréter, L	1
Gadaleta, CD; Goffredo, V; Paradiso, A; Ranieri, G	1
Fages, JF; Garcia, A; Hahl, M; Martin, RC; Narayanan, G; Tatum, C; Vàlek, V; Whitney, R	1
Baete, K; Deroose, CM; Haustermans, K; Koole, M; Mortelmans, L; Mottaghy, FM; Terwinghe, C; Van Binnebeek, S; Van Cutsem, E; Vanbilloen, B; Verbruggen, A; Verslype, C	1
Briel, M; Brunner, P; Imhof, A; Mäcke, HR; Marincek, N; Müller-Brand, J; Rasch, H; Rochlitz, C; Schindler, C; Walter, MA	1
Hoffmann, RT; Jakobs, TF; Paprottka, P; Reiser, MF; Trumm, CG	1
Alagöz, E; Arpaci, F; Arslan, N; Beyzadeoğlu, M; Emi, M; Oysul, K; Ozgüven, MA; Uğurel, S; Ustünsöz, B	1
Choyke, PL; Giesel, FL; Haberkorn, U; Haufe, S; Isermann, B; Kauczor, HU; Kratochwil, C; López-Benítez, R; Mier, W	1
Ashoori, N; Haug, A; Hoffmann, RT; Jakobs, TF; Paprottka, PM; Raessler, F; Reiser, MF; Schmidt, GP; Sommer, WH; Trumm, CG	1
Głowa, B; Hubalewska-Dydejczyk, AB; Jabrocka-Hybel, A; Królicki, L; Kunikowska, J; Mikołajczak, R; Pach, D; Pawlak, D; Sowa-Staszczak, A; Stefańska, A; Tomaszuk, M; Trofimiuk, M	1
Bilgic, S; Kucuk, O; Lacin, S; Oz, I; Ozkan, E	1
Buziak-Bereza, M; Gilis-Januszewska, A; Hubalewska-Dydejczyk, A; Jabrocka-Hybel, A; Krolicki, L; Kunikowska, J; Matyja, M; Mikolajczak, R; Pach, D; Sowa-Staszczak, A; Stefanska, A; Tomaszuk, M; Trofimiuk, M	1
Atassi, B; Benson, AB; Gates, VL; Gupta, R; Lewandowski, RJ; Memon, K; Miller, FH; Mulcahy, MF; Newman, S; Nikolaidis, P; Omary, RA; Riaz, A; Ryu, RK; Salem, R; Sato, KT; Yaghmai, V	1
Aljiffry, M; Cabrera, T; Chaudhury, P; Hassanain, M; Jamal, M; Khankan, A; Kongkaewpaisarn, N; Lisbona, R; Metrakos, P; Rivera, J; Salman, A; Shaheen, M; Simoneau, E; Valenti, D	1
Baio, SM; Bodei, L; Chinol, M; Cremonesi, M; Grana, CM; Paganelli, G; Severi, S	1
Briel, M; Brunner, P; Koller, MT; Mäcke, HR; Marincek, N; Müller-Brand, J; Ng, QK; Rochlitz, C; Romer, A; Schindler, C; Villard, L; Walter, MA	1
Reidy-Lagunes, D; Thornton, R	1
Kwekkeboom, DJ	1
Gabriel, M	1
Bartenstein, P; Baum, RP; Bengel, FM; Biersack, HJ; Dunkelmann, S; Ezziddin, S; Gratz, KF; Haug, A; Hörsch, D; Knapp, WH; Krause, BJ; Plöckinger, U; Schümichen, C; Schwartz-Fuchs, S	1
Cwikla, J; Gut, P; Handkiewicz-Junak, D; Hubalewska-Dydejczyk, A; Jakuciński, M; Kamiński, G; Kowalska, A; Królicki, L; Kunikowska, J; Lukiewicz, A; Mikolajczak, R; Pawlak, D; Sowa-Staszczak, A; Szaluś, N	1
Ahmadzadehfar, H; Biersack, HJ; Ezziddin, S; Haslerud, T; Kahancova, S; Meyer, C; Wilhelm, K; Willinek, W	1
Hanna, M; Mikko, T	1
Gleisner, KS; Ljungberg, M	1
Baechler, S; Boubaker, A; Dieudonné, A; Gardin, I; Hobbs, RF; Le Guludec, D; Lebtahi, R; Maurel, F; Sgouros, G; Wahl, RL	1
Briel, M; Brunner, P; Jörg, AC; Koller, MT; Maecke, HR; Marincek, N; Müller-Brand, J; Rochlitz, C; Schindler, C; Walter, MA	1
Mikolajczak, R; Parus, JL	1
Barone, R; Bouterfa, H; Carlier, P; Chen, T; de Camps, J; Jamar, F; Krenning, EP; Kvols, LK; Labar, D; Mathieu, I; Pauwels, S; Schran, H; Smith, MC; Valkema, R; Walrand, S	1
Bouterfa, H; Bushnell, D; Carlisle, T; Connolly, M; Karwal, M; Menda, Y; Miller, S; O'Dorisio, T; Parker, S; Zehr, P	1
Lewington, VJ	1
Bartolomei, M; Bodei, L; Chinol, M; Cremonesi, M; Grana, C; Paganelli, G; Rocca, P	1
Arnold, R; Bartenstein, P; Bouterfa, H; Buchholz, HG; Förster, GJ; Göke, B; Haus, U; Helisch, A; Pauwels, S; Reber, H; Weber, MM; Wiedenmann, B	1
Forrer, F; Maecke, H; Mueller-Brand, J	1
Bakker, WH; Barone, R; Bouterfa, H; Jamar, F; Krenning, EP; Kvols, LK; Kwekkeboom, DJ; Pauwels, S; Valkema, R	1
Besse, IM; Bushnell, DL; Juweid, ME; Madsen, MT; Menda, Y; O'Dorisio, MS; O'Dorisio, T	1
Bushnell, D	1
deHerder, WW; deJong, M; Krenning, EP; Kwekkeboom, DJ; Teunissen, JJ; Valkema, R	1
Angos, R; Betes, M; Bilbao, JI; Carretero, C; De la Riva, S; de Luis, E; Fernandez-Urien, I; Munoz-Navas, M; Sangro, B; Sola, J; Subtil, JC	1
Causer, L; Chittenden, S; Flux, GD; Hindorf, C; Lewington, VJ; Mäcke, HR	1
Ackermann, RJ; Andrews, JC; Cotton, LA; Ensminger, WD; Shapiro, B; Walker, SC	1
Behe, M; Bucher, HC; Goetze, M; Heppeler, A; Jermann, E; Maecke, HR; Mueller-Brand, J; Otte, A; Roser, HW	1
Dellas, S; Herrmann, R; Maecke, HR; Mueller-Brand, J; Nitzsche, EU; Otte, A	1
Buscombe, JR; Caplin, ME; Mielcarek, W	1
Bakker, WH; Kooij, PP; Krenning, EP; Kwekkeboom, DJ; Mäcke, HR	1
Herrmann, R; Mäcke, HR; Müller-Brand, J; Otte, A	1
Bernard, HF; Breeman, WA; De Jong, M; Kooij, PP; Krenning, EP; Kwekkeboom, DJ; Mäcke, HR; Slooter, GD; Valkema, R; Van Eijck, CH	1
Crazzolara, A; Haldemann, A; Maecke, HR; Mueller-Brand, J; Waldherr, C	1
Andreae, F; Angelberger, P; Dudczak, R; Flores, J; Halvadjieva, E; Havlik, E; Kurtaran, A; Leimer, M; Li, SR; Niederle, B; Novotny, C; Ofluoglu, S; Pangerl, T; Raderer, M; Smith-Jones, P; Traub, T; Virgolini, I	1
Bakker, W; Chen, T; Jamar, F; Krenning, E; Kvols, L; Liu, J; Pauwels, S; Schran, H; Smith, MC; Valkema, R; Yeh, CM	1
de Jong, M; Krenning, EP; Kwekkeboom, D	1
Bakker, WH; Breeman, WA; de Jong, M; Kooij, PP; Krenning, EP; Kwekkeboom, DJ; Valkema, R; Visser, TJ	1
Grossman, AB; Kaltsas, GA; Mukherjee, JJ	1
Cybulla, M; Otte, A; Weiner, SM	1
Bakker, WH; Breeman, WA; De Jong, M; Jamar, F; Krenning, EP; Kvols, LK; Kwekkeboom, DJ; Pauwels, S; Smith, C; Valkema, R	1
Crazzolara, A; Haldemann, A; Maecke, HR; Mueller-Brand, J; Nitzsche, EU; Pless, M; Schumacher, T; Waldherr, C	1
de Jong, M; Krenning, E	1

Reviews

35 review(s) available for yttrium radioisotopes and Neuroendocrine Tumors

Article	Year
Molecular imaging Theranostics of Neuroendocrine Tumors. Seminars in nuclear medicine, 2023, Volume: 53, Issue:4 Topics: Humans; Molecular Imaging; Neuroendocrine Tumors; Positron Emission Tomography Computed Tomography; Precision Medicine; Radiopharmaceuticals; Receptors, Somatostatin; Yttrium Radioisotopes	2023
Nephrotoxicity/renal failure after therapy with 90Yttrium- and 177Lutetium-radiolabeled somatostatin analogs in different types of neuroendocrine tumors: a systematic review. Nuclear medicine communications, 2020, Volume: 41, Issue:7 Topics: Humans; Isotope Labeling; Kidney; Lutetium; Neuroendocrine Tumors; Radioisotopes; Renal Insufficiency; Somatostatin; Yttrium Radioisotopes	2020
Molecular and Metabolic Imaging of Hepatic Neuroendocrine Tumors Following Radioembolization with 90Y-microspheres. Current medical imaging, 2020, Volume: 16, Issue:5 Topics: Brachytherapy; Fluorodeoxyglucose F18; Humans; Liver; Liver Neoplasms; Microspheres; Neuroendocrine Tumors; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Yttrium Radioisotopes	2020
Association between objective response rate and overall survival in metastatic neuroendocrine tumors treated with radioembolization: a systematic literature review and regression analysis. Expert review of anticancer therapy, 2020, Volume: 20, Issue:11 Topics: Combined Modality Therapy; Embolization, Therapeutic; Glass; Humans; Microspheres; Neoplasm Metastasis; Neuroendocrine Tumors; Randomized Controlled Trials as Topic; Regression Analysis; Survival Rate; Treatment Outcome; Yttrium Radioisotopes	2020
Liver-Directed Therapies for Neuroendocrine Neoplasms. Current oncology reports, 2021, 03-15, Volume: 23, Issue:4 Topics: Chemoembolization, Therapeutic; Clinical Trials as Topic; Holmium; Humans; Liver Neoplasms; Neuroendocrine Tumors; Radioisotopes; Radiotherapy; Yttrium Radioisotopes	2021
The efficacy of the available peptide receptor radionuclide therapy for neuroendocrine tumors: a meta-analysis. Nuclear medicine communications, 2017, Volume: 38, Issue:12 Topics: Humans; Lutetium; Neuroendocrine Tumors; Radioisotopes; Receptors, Peptide; Treatment Outcome; Yttrium Radioisotopes	2017
Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective. Nuclear medicine review. Central & Eastern Europe, 2018, Volume: 21, Issue:2 Topics: Humans; Intestinal Neoplasms; Lutetium; Neuroendocrine Tumors; Pancreatic Neoplasms; Radioisotopes; Receptors, Peptide; Stomach Neoplasms; Yttrium Radioisotopes	2018
Y90 Clinical Data Update: Cholangiocarcinoma, Neuroendocrine Tumor, Melanoma, and Breast Cancer Metastatic Disease. Techniques in vascular and interventional radiology, 2019, Volume: 22, Issue:2 Topics: Breast Neoplasms; Cholangiocarcinoma; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Melanoma; Microspheres; Neuroendocrine Tumors; Radiography, Interventional; Yttrium Radioisotopes	2019
Role of Radioembolization in Metastatic Neuroendocrine Tumors. Cardiovascular and interventional radiology, 2022, Volume: 45, Issue:11 Topics: Brachytherapy; Embolization, Therapeutic; Humans; Liver Neoplasms; Neuroendocrine Tumors; Yttrium Radioisotopes	2022
Radioembolisation with 90Y microspheres for neuroendocrine liver metastases: an institutional case series, systematic review and meta-analysis. HPB : the official journal of the International Hepato Pancreato Biliary Association, 2019, Volume: 21, Issue:7 Topics: Aged; Disease Progression; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Neuroendocrine Tumors; Progression-Free Survival; Radiopharmaceuticals; Retrospective Studies; Time Factors; Yttrium Radioisotopes	2019
Somatostatin receptor-based molecular imaging and therapy for neuroendocrine tumors. BioMed research international, 2013, Volume: 2013 Topics: Humans; Lutetium; Molecular Imaging; Neuroendocrine Tumors; Positron-Emission Tomography; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Yttrium Radioisotopes	2013
The efficacy of hepatic 90Y resin radioembolization for metastatic neuroendocrine tumors: a meta-analysis. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2014, Volume: 55, Issue:9 Topics: Embolization, Therapeutic; Humans; Liver Neoplasms; Neuroendocrine Tumors; Yttrium Radioisotopes	2014
Relevance of PET for pretherapeutic prediction of doses in peptide receptor radionuclide therapy. PET clinics, 2014, Volume: 9, Issue:1 Topics: Humans; Neuroendocrine Tumors; Octreotide; Positron-Emission Tomography; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage; Receptors, Peptide; Tomography, Emission-Computed, Single-Photon; Yttrium Radioisotopes	2014
68Gallium- and 90Yttrium-/ 177Lutetium: "theranostic twins" for diagnosis and treatment of NETs. Annals of nuclear medicine, 2015, Volume: 29, Issue:1 Topics: Gallium Radioisotopes; Humans; Lutetium; Neuroendocrine Tumors; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Yttrium Radioisotopes	2015
Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocrine-related cancer, 2010, Volume: 17, Issue:1 Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Digestive System Neoplasms; Gallium Radioisotopes; Humans; Indium Radioisotopes; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Organotechnetium Compounds; Peptides, Cyclic; Positron-Emission Tomography; Quality of Life; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Treatment Outcome; Yttrium Radioisotopes	2010
Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues. European review for medical and pharmacological sciences, 2010, Volume: 14, Issue:4 Topics: Antineoplastic Agents; Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide; Somatostatin; Yttrium Radioisotopes	2010
Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Endocrinology and metabolism clinics of North America, 2011, Volume: 40, Issue:1 Topics: Animals; Antineoplastic Agents; Gastrointestinal Neoplasms; Humans; Indium Radioisotopes; Lutetium; Molecular Targeted Therapy; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Yttrium Radioisotopes	2011
Targeted radiotherapy with radiolabeled somatostatin analogs. Endocrinology and metabolism clinics of North America, 2011, Volume: 40, Issue:1 Topics: Gastrointestinal Neoplasms; Humans; Indium Radioisotopes; Lutetium; Molecular Targeted Therapy; Neuroendocrine Tumors; Pancreatic Neoplasms; Patient Selection; Radiation Injuries; Radioisotopes; Radionuclide Imaging; Radiotherapy; Somatostatin; Yttrium Radioisotopes	2011
Yttrium-90 (90Y) in the principal radionuclide therapies: an efficacy correlation between peptide receptor radionuclide therapy, radioimmunotherapy and transarterial radioembolization therapy. Ten years of experience (1999-2009). Critical reviews in oncology/hematology, 2011, Volume: 80, Issue:3 Topics: Antibodies, Monoclonal; Carcinoma, Hepatocellular; Clinical Trials as Topic; Embolization, Therapeutic; Humans; Liver Neoplasms; Lymphoma, Non-Hodgkin; Neoplasms; Neuroendocrine Tumors; Radioimmunotherapy; Receptors, Peptide; Treatment Outcome; Yttrium Radioisotopes	2011
Arterial therapies of non-colorectal cancer metastases to the liver (from chemoembolization to radioembolization). Abdominal imaging, 2011, Volume: 36, Issue:6 Topics: Antineoplastic Agents; Breast Neoplasms; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Melanoma; Microspheres; Neuroendocrine Tumors; Pancreatic Neoplasms; Yttrium Radioisotopes	2011
Yttrium-labelled peptides for therapy of NET. European journal of nuclear medicine and molecular imaging, 2012, Volume: 39 Suppl 1 Topics: Bone Marrow; Clinical Trials as Topic; Humans; Kidney; Lutetium; Neuroendocrine Tumors; Octreotide; Peptides; Radioisotopes; Radiopharmaceuticals; Radiotherapy Dosage; Receptors, Peptide; Safety; Treatment Outcome; Yttrium Radioisotopes	2012
Pancreatic neuroendocrine and carcinoid tumors: what's new, what's old, and what's different? Current oncology reports, 2012, Volume: 14, Issue:3 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoid Tumor; Combined Modality Therapy; Dacarbazine; Embolization, Therapeutic; Everolimus; Humans; Immunosuppressive Agents; Indoles; Neuroendocrine Tumors; Pancreatic Neoplasms; Pyrroles; Sirolimus; Streptozocin; Sunitinib; Temozolomide; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factors; Yttrium Radioisotopes	2012
Radionuclide therapy beyond radioiodine. Wiener medizinische Wochenschrift (1946), 2012, Volume: 162, Issue:19-20 Topics: Bone Neoplasms; Gamma Rays; Humans; Iodine Radioisotopes; Liver Neoplasms; Lymphoma; Neoplasms; Neuroendocrine Tumors; Palliative Care; Radiation Protection; Radioimmunotherapy; Radioisotopes; Receptors, Somatostatin; Thyroid Neoplasms; Yttrium Radioisotopes	2012
Beta-emitting radionuclides for peptide receptor radionuclide therapy. Current topics in medicinal chemistry, 2012, Volume: 12, Issue:23 Topics: Beta Particles; Chelating Agents; Humans; Isotope Labeling; Ligands; Lutetium; Neuroendocrine Tumors; Radioactivity; Radioisotopes; Radionuclide Imaging; Radiotherapy; Receptors, Somatostatin; Somatostatin; Yttrium Radioisotopes	2012
Targeted radionuclide therapy for neuroendocrine tumours. Endocrine-related cancer, 2003, Volume: 10, Issue:4 Topics: 3-Iodobenzylguanidine; Antineoplastic Agents; Humans; Iodine Radioisotopes; Neuroendocrine Tumors; Peptides, Cyclic; Radiopharmaceuticals; Somatostatin; Yttrium Radioisotopes	2003
Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. European journal of nuclear medicine and molecular imaging, 2004, Volume: 31, Issue:7 Topics: Animals; Humans; Kidney Diseases; Neuroendocrine Tumors; Octreotide; Radiation Injuries; Radiopharmaceuticals; Radiotherapy; Treatment Outcome; Yttrium Radioisotopes	2004
Therapy with radiolabeled somatostatin peptide analogs for metastatic neuroendocrine tumors. Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2006, Volume: 10, Issue:3 Topics: Clinical Trials as Topic; Humans; Neoplasm Metastasis; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Radionuclide Imaging; Somatostatin; Yttrium Radioisotopes	2006
Molecular radiotherapy with somatostatin analogs for (neuro-)endocrine tumors. Journal of endocrinological investigation, 2005, Volume: 28, Issue:11 Suppl I Topics: Humans; Indium Radioisotopes; Isotope Labeling; Lutetium; Neuroendocrine Tumors; Radioisotopes; Receptors, Somatostatin; Somatostatin; Yttrium Radioisotopes	2005
Radiolabelled somatostatins: towards the magic bullet? Nuclear medicine communications, 1999, Volume: 20, Issue:4 Topics: Humans; Indium Radioisotopes; Neuroendocrine Tumors; Octreotide; Palliative Care; Radiopharmaceuticals; Yttrium Radioisotopes	1999
New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy. The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), 2000, Volume: 44, Issue:1 Topics: Humans; Indium Radioisotopes; Neuroendocrine Tumors; Octreotide; Peptides, Cyclic; Radionuclide Imaging; Radiopharmaceuticals; Somatostatin; Yttrium Radioisotopes	2000
OctreoTher: ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy. Digestion, 2000, Volume: 62 Suppl 1 Topics: Animals; Breast Neoplasms; Carcinoma, Small Cell; Dose-Response Relationship, Radiation; Female; Humans; Indium Radioisotopes; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasms; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Yttrium Radioisotopes	2000
Peptide receptor imaging and therapy. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2000, Volume: 41, Issue:10 Topics: Humans; Indium Radioisotopes; Neoplasms; Neuroendocrine Tumors; Octreotide; Oligopeptides; Pentetic Acid; Radiopharmaceuticals; Receptors, Somatostatin; Tomography, Emission-Computed, Single-Photon; Yttrium Radioisotopes	2000
Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. European journal of nuclear medicine, 2001, Volume: 28, Issue:9 Topics: Humans; Indium Radioisotopes; Lutetium; Neuroendocrine Tumors; Octreotide; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Yttrium Radioisotopes	2001
The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours. Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12 Suppl 2 Topics: 3-Iodobenzylguanidine; Humans; Iodine Radioisotopes; Neuroendocrine Tumors; Octreotide; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Somatostatin; Yttrium Radioisotopes	2001
Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Seminars in nuclear medicine, 2002, Volume: 32, Issue:2 Topics: Animals; Humans; Indium Radioisotopes; Liver Neoplasms; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Pentetic Acid; Radiopharmaceuticals; Rats; Receptors, Somatostatin; Tumor Cells, Cultured; Yttrium Radioisotopes	2002

Trials

19 trial(s) available for yttrium radioisotopes and Neuroendocrine Tumors

Article	Year
Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials. ESMO open, 2021, Volume: 6, Issue:4 Topics: Adrenal Gland Neoplasms; Biomarkers; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Paraganglioma; Pheochromocytoma; Positron Emission Tomography Computed Tomography; Prognosis; Receptors, Somatostatin; Yttrium Radioisotopes	2021
Radioembolization Versus Bland Embolization for Hepatic Metastases from Small Intestinal Neuroendocrine Tumors: Short-Term Results of a Randomized Clinical Trial. World journal of surgery, 2018, Volume: 42, Issue:2 Topics: Adult; Aged; Diffusion Magnetic Resonance Imaging; Embolization, Therapeutic; Female; Hepatic Artery; Humans; Intestinal Neoplasms; Intestine, Small; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Pilot Projects; Prospective Studies; Treatment Outcome; Yttrium Radioisotopes	2018
Nephrotoxicity after PRRT - still a serious clinical problem? Renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATATE and 90Y/177Lu-DOTATATE. Endokrynologia Polska, 2013, Volume: 64, Issue:1 Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Kidney; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Renal Insufficiency; Yttrium Radioisotopes	2013
90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study. Journal of gastrointestinal cancer, 2014, Volume: 45, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Feasibility Studies; Female; Follow-Up Studies; Gastrointestinal Neoplasms; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Pilot Projects; Prognosis; Prospective Studies; Yttrium Radioisotopes	2014
Individualized dosimetry-based activity reduction of ⁹⁰Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy. European journal of nuclear medicine and molecular imaging, 2014, Volume: 41, Issue:6 Topics: Adult; Aged; Digestive System Neoplasms; Female; Humans; Kidney; Kidney Function Tests; Lung Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Precision Medicine; Radiation Dosage; Radiometry; Radionuclide Imaging; Radiopharmaceuticals; Yttrium Radioisotopes	2014
Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. European journal of nuclear medicine and molecular imaging, 2015, Volume: 42, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Female; Humans; Leukemia, Myeloid, Acute; Lutetium; Male; Middle Aged; Myelodysplastic Syndromes; Neuroendocrine Tumors; Octreotide; Radiation Dosage; Radiopharmaceuticals; Receptors, Peptide; Yttrium Radioisotopes	2015
90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Annals of surgery, 2008, Volume: 247, Issue:6 Topics: Analysis of Variance; Female; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Neuroendocrine Tumors; Positron-Emission Tomography; Radiotherapy Dosage; Tomography, X-Ray Computed; Treatment Outcome; Yttrium Radioisotopes	2008
Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer, 2008, Sep-01, Volume: 113, Issue:5 Topics: Adult; Aged; Brachytherapy; Embolization, Therapeutic; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Microspheres; Middle Aged; Neuroendocrine Tumors; Prospective Studies; Tomography, X-Ray Computed; Yttrium Radioisotopes	2008
Selective internal radiotherapy with Yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study. Digestion, 2009, Volume: 79, Issue:3 Topics: Adult; Aged; Citrates; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Neuroendocrine Tumors; Organometallic Compounds; Quality of Life; Treatment Outcome; Yttrium Radioisotopes	2009
Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jun-10, Volume: 29, Issue:17 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Yttrium Radioisotopes	2011
Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases. Endocrine-related cancer, 2011, Volume: 18, Issue:5 Topics: Adult; Aged; Chromogranin A; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Pilot Projects; Positron-Emission Tomography; Radiopharmaceuticals; Tomography, X-Ray Computed; Yttrium Radioisotopes	2011
Intra-arterial treatment with 90yttrium microspheres in treatment-refractory and unresectable liver metastases of neuroendocrine tumors and the use of 111in-octreotide scintigraphy in the evaluation of treatment response. Cancer biotherapy & radiopharmaceuticals, 2011, Volume: 26, Issue:5 Topics: Adult; Aged; Female; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Microspheres; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Octreotide; Radionuclide Imaging; Radiotherapy Dosage; Survival Analysis; Treatment Outcome; Yttrium Radioisotopes	2011
Somatostatin-based radiotherapy with [90Y-DOTA]-TOC in neuroendocrine tumors: long-term outcome of a phase I dose escalation study. Journal of translational medicine, 2013, Jan-15, Volume: 11 Topics: Adolescent; Adult; Aged; Dose-Response Relationship, Radiation; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Radiotherapy; Somatostatin; Young Adult; Yttrium Radioisotopes	2013
86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487)--a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. European journal of nuclear medicine and molecular imaging, 2003, Volume: 30, Issue:4 Topics: Adult; Aged; Amino Acids; Arginine; Cohort Studies; Cross-Over Studies; Dizziness; Drug Combinations; Female; Humans; Infusions, Intravenous; Kidney; Lysine; Male; Metabolic Clearance Rate; Middle Aged; Neuroendocrine Tumors; Octreotide; Organ Specificity; Radiation Dosage; Radiation Injuries; Radiation-Protective Agents; Radiometry; Radiopharmaceuticals; Tissue Distribution; Tomography, Emission-Computed; Vomiting; Yttrium Radioisotopes	2003
Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2003, Volume: 44, Issue:10 Topics: Adult; Aged; Dose-Response Relationship, Radiation; Female; Humans; Injections, Intravenous; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Quality of Life; Radiography; Radiopharmaceuticals; Radiotherapy Dosage; Treatment Outcome; Yttrium Radioisotopes	2003
Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours. European journal of nuclear medicine and molecular imaging, 2004, Volume: 31, Issue:10 Topics: Body Burden; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neuroendocrine Tumors; Octreotide; Organ Specificity; Radiation Injuries; Radiation Protection; Radiometry; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Relative Biological Effectiveness; Risk Assessment; Risk Factors; Somatostatin; Tissue Distribution; Yttrium Radioisotopes	2004
Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors. Seminars in nuclear medicine, 2006, Volume: 36, Issue:2 Topics: Adult; Aged; Female; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Survival Rate; Yttrium Radioisotopes	2006
Dosimetry for (90)Y-DOTATOC therapies in patients with neuroendocrine tumors. Cancer biotherapy & radiopharmaceuticals, 2007, Volume: 22, Issue:1 Topics: Adult; Aged; Dose-Response Relationship, Radiation; Female; Humans; Kidney; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Radiometry; Yttrium Radioisotopes	2007
Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1994, Volume: 35, Issue:10 Topics: Adult; Aged; Brachytherapy; Colorectal Neoplasms; Female; Follow-Up Studies; Glass; Hepatic Artery; Humans; Liver; Liver Neoplasms; Male; Microspheres; Middle Aged; Neuroendocrine Tumors; Radionuclide Imaging; Radiotherapy Dosage; Technetium Tc 99m Aggregated Albumin; Time Factors; Yttrium Radioisotopes	1994

Other Studies

83 other study(ies) available for yttrium radioisotopes and Neuroendocrine Tumors

Article	Year
Dose-response relationship after yttrium-90-radioembolization with glass microspheres in patients with neuroendocrine tumor liver metastases. European journal of nuclear medicine and molecular imaging, 2022, Volume: 49, Issue:5 Topics: Embolization, Therapeutic; Humans; Liver Neoplasms; Microspheres; Neuroendocrine Tumors; Positron Emission Tomography Computed Tomography; Retrospective Studies; Yttrium Radioisotopes	2022
Hepatic complications of peptide receptor radionuclide therapy with Lutetium-177 and Yttrium-90 in patients with neuroendocrine neoplasm. Nuclear medicine review. Central & Eastern Europe, 2022, Volume: 25, Issue:1 Topics: Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Positron-Emission Tomography; Radioisotopes; Radionuclide Imaging; Receptors, Peptide; Yttrium Radioisotopes	2022
Long-term outcomes following 90Y Radioembolization of neuroendocrine liver metastases: evaluation of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry. BMC cancer, 2022, Mar-01, Volume: 22, Issue:1 Topics: Aged; Embolization, Therapeutic; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Registries; Survival Rate; Treatment Outcome; Yttrium Radioisotopes	2022
Optimized cocktail of 90Y/177Lu for radionuclide therapy of neuroendocrine tumors of various sizes: a simulation study. Nuclear medicine communications, 2022, Jun-01, Volume: 43, Issue:6 Topics: Computer Simulation; Humans; Monte Carlo Method; Neuroendocrine Tumors; Radiopharmaceuticals; Yttrium Radioisotopes	2022
Potential value of pre- and post-therapy [68Ga]Ga-DOTA-TATE PET/CT in the prognosis of response to PRRT in disseminated neuroendocrine tumors. Frontiers in endocrinology, 2022, Volume: 13 Topics: Heterocyclic Compounds, 1-Ring; Humans; Neuroendocrine Tumors; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Yttrium Radioisotopes	2022
Long-Term Complications of Radioligand Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms. Nutrients, 2022, Dec-30, Volume: 15, Issue:1 Topics: Humans; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Yttrium Radioisotopes	2022
Peptide Receptor Radionuclide Therapy in Patients With Advanced Progressive Medullary Thyroid Cancer: Efficacy, Safety, and Survival Predictors. Clinical nuclear medicine, 2023, Mar-01, Volume: 48, Issue:3 Topics: Adult; Disease Progression; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Receptors, Peptide; Retrospective Studies; Thyroid Neoplasms; Yttrium Radioisotopes	2023
Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis. Journal of the American College of Surgeons, 2020, Volume: 230, Issue:4 Topics: Aged; Chemoembolization, Therapeutic; Embolization, Therapeutic; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Retrospective Studies; Treatment Outcome; Yttrium Radioisotopes	2020
Y90 selective internal radiation therapy and peptide receptor radionuclide therapy for the treatment of metastatic neuroendocrine tumors: combination or not? Nuclear medicine communications, 2020, Volume: 41, Issue:12 Topics: Adult; Cohort Studies; Female; Humans; Liver Neoplasms; Male; Neoplasm Metastasis; Neuroendocrine Tumors; Progression-Free Survival; Receptors, Somatostatin; Retrospective Studies; Yttrium Radioisotopes	2020
Prior Resection of the Primary Tumor Prolongs Survival After Peptide Receptor Radionuclide Therapy of Advanced Neuroendocrine Neoplasms. Annals of surgery, 2021, 07-01, Volume: 274, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Lutetium; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radioisotopes; Radiopharmaceuticals; Radiotherapy, Adjuvant; Retrospective Studies; Survival Analysis; Treatment Outcome; Yttrium Radioisotopes	2021
Efficacy and Prognostic Factors for Y-90 Radioembolization (Y-90) in Metastatic Neuroendocrine Tumors with Liver Metastases. Canadian journal of gastroenterology & hepatology, 2020, Volume: 2020 Topics: Adult; Aged; British Columbia; Humans; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Prognosis; Retrospective Studies; Treatment Outcome; Young Adult; Yttrium Radioisotopes	2020
225Ac-DOTATOC-Targeted Somatostatin Receptor α-Therapy in a Patient With Metastatic Neuroendocrine Tumor of the Thymus, Refractory to β-Radiation. Clinical nuclear medicine, 2021, Dec-01, Volume: 46, Issue:12 Topics: Actinium; Humans; Neuroendocrine Tumors; Octreotide; Receptors, Somatostatin; Yttrium Radioisotopes	2021
Long-Term Hepatotoxicity of Yttrium-90 Radioembolization as Treatment of Metastatic Neuroendocrine Tumor to the Liver. Journal of vascular and interventional radiology : JVIR, 2017, Volume: 28, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Radiation Dosage; Radiology, Interventional; Retrospective Studies; Treatment Outcome; Yttrium Radioisotopes	2017
Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model. European radiology, 2017, Volume: 27, Issue:12 Topics: ADAM17 Protein; Adult; Aged; Biomarkers, Tumor; Chemoembolization, Therapeutic; Epidemiologic Methods; Female; Gastrointestinal Neoplasms; Humans; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Radiopharmaceuticals; Treatment Outcome; Yttrium Radioisotopes	2017
Tumor Dose Response in Yttrium-90 Resin Microsphere Embolization for Neuroendocrine Liver Metastases: A Tumor-Specific Analysis with Dose Estimation Using SPECT-CT. Journal of vascular and interventional radiology : JVIR, 2017, Volume: 28, Issue:11 Topics: Dose-Response Relationship, Radiation; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Multimodal Imaging; Neuroendocrine Tumors; Radiopharmaceuticals; Radiotherapy Dosage; Technetium Tc 99m Aggregated Albumin; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Treatment Outcome; Yttrium Radioisotopes	2017
Long-Term Toxicity after Transarterial Radioembolization with Yttrium-90 Using Resin Microspheres for Neuroendocrine Tumor Liver Metastases. Journal of vascular and interventional radiology : JVIR, 2018, Volume: 29, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Neuroendocrine Tumors; Radiography, Interventional; Retrospective Studies; Survival Rate; Treatment Outcome; Yttrium Radioisotopes	2018
Safety and Feasibility of Integrating Yttrium-90 Radioembolization With Capecitabine-Temozolomide for Grade 2 Liver-Dominant Metastatic Neuroendocrine Tumors. Pancreas, 2018, Volume: 47, Issue:8 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Embolization, Therapeutic; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Temozolomide; Thrombocytopenia; Yttrium Radioisotopes	2018
A five-compartment biokinetic model for Medical physics, 2018, Volume: 45, Issue:12 Topics: Adult; Aged; Female; Humans; Kidney; Male; Middle Aged; Models, Biological; Monte Carlo Method; Neuroendocrine Tumors; Octreotide; Radiotherapy Dosage; Yttrium Radioisotopes	2018
Neuroendocrine Liver Metastases. Cardiovascular and interventional radiology, 2019, Volume: 42, Issue:7 Topics: Humans; Liver Neoplasms; Microspheres; Neuroendocrine Tumors; Yttrium Radioisotopes	2019
Neuroendocrine tumor liver metastases treated with yttrium-90 radioembolization. Contemporary clinical trials, 2016, Volume: 50 Topics: Age Factors; Aged; Aged, 80 and over; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Neuroendocrine Tumors; Prognosis; Retrospective Studies; Xenopus Proteins; Yttrium Radioisotopes; Zinc Finger Protein Gli3	2016
Single-institution experience of radioembolization with yttrium-90 microspheres for unresectable metastatic neuroendocrine liver tumors. Journal of gastroenterology and hepatology, 2017, Volume: 32, Issue:9 Topics: Aged; Embolization, Therapeutic; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Microspheres; Middle Aged; Neuroendocrine Tumors; Radiopharmaceuticals; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Yttrium Radioisotopes	2017
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022, Volume: 63, Issue:5 Topics: Brachytherapy; Embolization, Therapeutic; Humans; Liver Neoplasms; Neuroendocrine Tumors; Retrospective Studies; Treatment Outcome; Yttrium Radioisotopes	2022
Radioembolization with Cardiovascular and interventional radiology, 2020, Volume: 43, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Brachytherapy; Female; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Neuroendocrine Tumors; Receptors, Peptide; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Treatment Outcome; Yttrium Radioisotopes	2020
Radioembolization Versus Chemoembolization for Neuroendocrine Metastases. Journal of vascular and interventional radiology : JVIR, 2021, Volume: 32, Issue:3 Topics: Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury; Chemoembolization, Therapeutic; Embolization, Therapeutic; Humans; Liver Neoplasms; Neuroendocrine Tumors; Yttrium Radioisotopes	2021
Radioembolization with Cardiovascular and interventional radiology, 2019, Volume: 42, Issue:3 Topics: Brachytherapy; Follow-Up Studies; Humans; Liver Neoplasms; Microspheres; Neuroendocrine Tumors; Retrospective Studies; Survival Analysis; Treatment Outcome; Yttrium Radioisotopes	2019
Radioembolization for treatment of liver metastases from neuroendocrine tumors: correlation with imaging and biomarkers. Pancreas, 2013, Volume: 42, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Digestive System Neoplasms; Embolization, Therapeutic; Female; Humans; Intestinal Neoplasms; Kidney Neoplasms; Liver Neoplasms; Male; Microspheres; Middle Aged; Neuroendocrine Tumors; Pancreatic Neoplasms; Radiography; Retrospective Studies; Time Factors; Treatment Outcome; Yttrium Radioisotopes	2013
Peptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity. British journal of cancer, 2013, Apr-16, Volume: 108, Issue:7 Topics: Female; Humans; Intestinal Neoplasms; Intestine, Small; Lung Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Radiopharmaceuticals; Receptors, Peptide; Retrospective Studies; Survival Analysis; Treatment Outcome; Yttrium Radioisotopes	2013
Peptide receptor radionuclide therapy (PRRT) for GEP-NETs. Best practice & research. Clinical gastroenterology, 2012, Volume: 26, Issue:6 Topics: Heterocyclic Compounds; Heterocyclic Compounds, 1-Ring; Humans; Intestinal Neoplasms; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Peptides, Cyclic; Radiopharmaceuticals; Receptors, Somatostatin; Retreatment; Somatostatin; Stomach Neoplasms; Yttrium Radioisotopes	2012
Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence. European journal of nuclear medicine and molecular imaging, 2013, Volume: 40, Issue:8 Topics: Aged; Female; Humans; Intestinal Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Radiopharmaceuticals; Somatostatin; Stomach Neoplasms; Treatment Outcome; Yttrium Radioisotopes	2013
Clinical and laboratory toxicity after intra-arterial radioembolization with (90)y-microspheres for unresectable liver metastases. PloS one, 2013, Volume: 8, Issue:7 Topics: Aged; Colorectal Neoplasms; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Microspheres; Middle Aged; Neuroendocrine Tumors; Retrospective Studies; Yttrium Radioisotopes	2013
Different technical possibilities of post-therapeutic tandem 90Y/ /177Lu-DOTATATE imaging. Nuclear medicine review. Central & Eastern Europe, 2013, Volume: 16, Issue:2 Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Positron-Emission Tomography; Yttrium Radioisotopes	2013
Towards new response criteria in neuroendocrine tumors: which changes in MRI parameters are associated with longer progression-free survival after radioembolization of liver metastases? Journal of magnetic resonance imaging : JMRI, 2015, Volume: 41, Issue:2 Topics: Adult; Aged; Contrast Media; Disease-Free Survival; Embolization, Therapeutic; Female; Gadolinium DTPA; Humans; Image Interpretation, Computer-Assisted; Liver Neoplasms; Magnetic Resonance Imaging; Male; Microspheres; Middle Aged; Neoplasm Grading; Neuroendocrine Tumors; Retrospective Studies; Treatment Outcome; Yttrium Radioisotopes	2015
Yttrium-90 resin microsphere radioembolization using an antireflux catheter: an alternative to traditional coil embolization for nontarget protection. Cardiovascular and interventional radiology, 2015, Volume: 38, Issue:2 Topics: Adult; Aged; Brachytherapy; Catheters; Colorectal Neoplasms; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Neuroendocrine Tumors; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome; Yttrium Radioisotopes	2015
Radioembolization in the treatment of neuroendocrine tumors of the pancreas. JOP : Journal of the pancreas, 2014, Jul-28, Volume: 15, Issue:4 Topics: Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Neuroendocrine Tumors; Pancreatic Neoplasms; Radiopharmaceuticals; Radiotherapy Dosage; Survival Analysis; Treatment Outcome; Yttrium Radioisotopes	2014
PET optimization for improved assessment and accurate quantification of 90Y-microsphere biodistribution after radioembolization. Medical physics, 2014, Volume: 41, Issue:9 Topics: Adenocarcinoma; Aged; Brachytherapy; Carcinoma, Hepatocellular; Cholangiocarcinoma; Colorectal Neoplasms; Computer Simulation; Embolization, Therapeutic; Esophageal Neoplasms; Humans; Liver; Liver Neoplasms; Male; Microspheres; Middle Aged; Neuroendocrine Tumors; Phantoms, Imaging; Positron-Emission Tomography; Radiation Dosage; Signal-To-Noise Ratio; Tissue Distribution; Yttrium Radioisotopes	2014
Neoadjuvant ANZ journal of surgery, 2017, Volume: 87, Issue:1-2 Topics: Biopsy; Colonoscopes; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neuroendocrine Tumors; Positron-Emission Tomography; Rectal Neoplasms; Tomography, X-Ray Computed; Yttrium Radioisotopes	2017
The difference between medicine and magic is that magicians know what they are doing. European journal of nuclear medicine and molecular imaging, 2015, Volume: 42, Issue:1 Topics: Female; Humans; Lutetium; Male; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Yttrium Radioisotopes	2015
Systematic evaluation of tumoral 99mTc-MAA uptake using SPECT and SPECT/CT in 502 patients before 90Y radioembolization. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2015, Volume: 56, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Albumins; Angiography, Digital Subtraction; Breast Neoplasms; Carcinoma, Hepatocellular; Cholangiocarcinoma; Cohort Studies; Colorectal Neoplasms; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Retrospective Studies; Technetium Tc 99m Aggregated Albumin; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Urologic Neoplasms; Yttrium Radioisotopes	2015
(90)Y-PET/CT Imaging Quantification for Dosimetry in Peptide Receptor Radionuclide Therapy: Analysis and Corrections of the Impairing Factors. Cancer biotherapy & radiopharmaceuticals, 2015, Volume: 30, Issue:5 Topics: Aged; Humans; Kidney; Liver Neoplasms; Male; Middle Aged; Multimodal Imaging; Neuroendocrine Tumors; Pancreatic Neoplasms; Phantoms, Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Receptors, Somatostatin; Signal-To-Noise Ratio; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Yttrium Radioisotopes	2015
PET/CT and Bremsstrahlung Imaging After 90Y DOTANOC Therapy for Rectal Net With Liver Metastases. Clinical nuclear medicine, 2015, Volume: 40, Issue:10 Topics: Humans; Liver Neoplasms; Lutetium; Male; Middle Aged; Multimodal Imaging; Neuroendocrine Tumors; Organometallic Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Rectal Neoplasms; Tomography, X-Ray Computed; Yttrium Radioisotopes	2015
90Y Radioembolization Lung Shunt Fraction in Primary and Metastatic Liver Cancer as a Biomarker for Survival. Clinical nuclear medicine, 2016, Volume: 41, Issue:1 Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers; Cholangiocarcinoma; Colorectal Neoplasms; Embolization, Therapeutic; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung; Lung Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Pulmonary Ventilation; Radionuclide Imaging; Retrospective Studies; Technetium Tc 99m Aggregated Albumin; Tumor Burden; Yttrium Radioisotopes	2016
Therapeutic schemes in 177Lu and 90Y-PRRT: radiobiological considerations. The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 2017, Volume: 61, Issue:2 Topics: Adult; Algorithms; Female; Humans; Kidney; Lutetium; Male; Middle Aged; Models, Biological; Neuroendocrine Tumors; Organs at Risk; Radioisotopes; Radiometry; Radiotherapy; Receptors, Peptide; Yttrium Radioisotopes	2017
Optimized Peptide Amount and Activity for ⁹⁰Y-Labeled DOTATATE Therapy. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2016, Volume: 57, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Bone Marrow; Computer Simulation; Female; Gamma Cameras; Humans; Kidney; Male; Meningioma; Middle Aged; Models, Biological; Models, Theoretical; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Regional Blood Flow; Tissue Distribution; Yttrium Radioisotopes	2016
Lung Shunt Fraction prior to Yttrium-90 Radioembolization Predicts Survival in Patients with Neuroendocrine Liver Metastases: Single-Center Prospective Analysis. Cardiovascular and interventional radiology, 2016, Volume: 39, Issue:7 Topics: Aged; Brachytherapy; Female; Humans; Liver Neoplasms; Lung; Male; Middle Aged; Neuroendocrine Tumors; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Survival Analysis; Treatment Outcome; Yttrium Radioisotopes	2016
Myeloid neoplasms after chemotherapy and PRRT: myth and reality. Endocrine-related cancer, 2016, Volume: 23, Issue:8 Topics: Hematologic Neoplasms; Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Receptors, Peptide; Yttrium Radioisotopes	2016
Neurokinin A monitoring of response to interferon alpha in a patient with an advanced small bowel neuroendocrine tumour uncontrolled by somatostatin analogue therapy. Annals of clinical biochemistry, 2017, Volume: 54, Issue:2 Topics: Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Carcinoid Tumor; Disease Progression; Drug Monitoring; Female; Humans; Interferon-alpha; Intestinal Neoplasms; Liver Neoplasms; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Neurokinin A; Somatostatin; Yttrium Radioisotopes	2017
Prospective Longitudinal Quality of Life Assessment in Patients With Neuroendocrine Tumor Liver Metastases Treated With 90Y Radioembolization. Clinical nuclear medicine, 2016, Volume: 41, Issue:12 Topics: Adult; Aged; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Prospective Studies; Quality of Life; Radiopharmaceuticals; Yttrium Radioisotopes	2016
Liver Resection After Selective Internal Radiation Therapy with Yttrium-90 is Safe and Feasible: A Bi-institutional Analysis. Annals of surgical oncology, 2017, Volume: 24, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Brachytherapy; Carcinoma, Hepatocellular; Colorectal Neoplasms; Embolization, Therapeutic; Eye Neoplasms; Hepatectomy; Humans; Length of Stay; Liver Neoplasms; Melanoma; Middle Aged; Neuroendocrine Tumors; Patient Readmission; Postoperative Complications; Radiopharmaceuticals; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Tomography, X-Ray Computed; Yttrium Radioisotopes	2017
Effect of Substituting 50% Isovue for Sterile Water as the Delivery Medium for SIR-Spheres: Improved Dose Delivery and Decreased Incidence of Stasis. Clinical nuclear medicine, 2017, Volume: 42, Issue:3 Topics: Aged; Brachytherapy; Colorectal Neoplasms; Contrast Media; Drug Delivery Systems; Embolization, Therapeutic; Female; Humans; Iopamidol; Liver Neoplasms; Male; Microspheres; Middle Aged; Neuroendocrine Tumors; Retrospective Studies; Treatment Outcome; Water; Yttrium Radioisotopes	2017
Severe coagulopathy after 90Y microsphere administration: resemblance to the Kasabach-Merritt syndrome. Journal of vascular and interventional radiology : JVIR, 2008, Volume: 19, Issue:7 Topics: Brachytherapy; Diagnosis, Differential; Disseminated Intravascular Coagulation; Hematoma; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Neuroendocrine Tumors; Radiation Injuries; Radiopharmaceuticals; Severity of Illness Index; Syndrome; Yttrium Radioisotopes	2008
[Peptide receptor radionuclide therapy of neuroendocrine tumors]. Ugeskrift for laeger, 2009, Mar-23, Volume: 171, Issue:13 Topics: Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide; Receptors, Somatostatin; Yttrium Radioisotopes	2009
Role of interventional radiology in the treatment of patients with neuroendocrine metastases in the liver. Journal of the National Comprehensive Cancer Network : JNCCN, 2009, Volume: 7, Issue:7 Topics: Catheter Ablation; Chemoembolization, Therapeutic; Cryosurgery; Embolization, Therapeutic; Ethanol; Hepatic Artery; Humans; Injections; Lasers, Solid-State; Liver Neoplasms; Neuroendocrine Tumors; Radiology, Interventional; Radiopharmaceuticals; Solvents; Yttrium Radioisotopes	2009
[Liver chemoembolization: an update]. Bulletin du cancer, 2009, Volume: 96, Issue:11 Topics: Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Contraindications; Hepatic Artery; Humans; Iodized Oil; Liver Neoplasms; Neuroendocrine Tumors; Yttrium Radioisotopes	2009
Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. The British journal of surgery, 2010, Volume: 97, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Embolization, Therapeutic; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Microspheres; Middle Aged; Neuroendocrine Tumors; Prospective Studies; Radiopharmaceuticals; Yttrium Radioisotopes	2010
[Somatostatin receptor endoradiotherapy of neuroendocrine tumors: experience in Hungarian patients]. Orvosi hetilap, 2011, Mar-06, Volume: 152, Issue:10 Topics: Adult; Aged; Female; Humans; Hungary; Indium Radioisotopes; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Radioisotopes; Radiotherapy; Receptors, Somatostatin; Remission Induction; Yttrium Radioisotopes	2011
Transarterial chemoembolization and selective internal radiation for the treatment of patients with metastatic neuroendocrine tumors: a comparison of efficacy and cost. The oncologist, 2011, Volume: 16, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Chemoembolization, Therapeutic; Combined Modality Therapy; Cost-Benefit Analysis; Doxorubicin; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Treatment Outcome; Yttrium Radioisotopes	2011
Altered biodistribution of somatostatin analogues after first cycle of Peptide receptor radionuclide therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jul-01, Volume: 29, Issue:19 Topics: Adult; Disease Progression; Female; Humans; Indium Radioisotopes; Intestinal Neoplasms; Liver Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Neoplasm Metastasis; Neuroendocrine Tumors; Octreotide; Positron-Emission Tomography; Radioisotopes; Receptors, Peptide; Somatostatin; Tomography, X-Ray Computed; Yttrium Radioisotopes	2011
Selective intraarterial radionuclide therapy with Yttrium-90 (Y-90) microspheres for hepatic neuroendocrine metastases: initial experience at a single center. Vojnosanitetski pregled, 2011, Volume: 68, Issue:4 Topics: Adult; Aged; Embolization, Therapeutic; Female; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Microspheres; Middle Aged; Neuroendocrine Tumors; Radiopharmaceuticals; Yttrium Radioisotopes	2011
Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres. Cardiovascular and interventional radiology, 2012, Volume: 35, Issue:2 Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Digestive System Diseases; Embolization, Therapeutic; Fatigue; Female; Fever; Follow-Up Studies; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Neuroendocrine Tumors; Radiation Dosage; Retrospective Studies; Yttrium Radioisotopes	2012
Repeated cycles of peptide receptor radionuclide therapy (PRRT)--results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2012, Volume: 102, Issue:1 Topics: Aged; Diagnostic Imaging; Disease Progression; Female; Humans; Lutetium; Male; Middle Aged; Neoadjuvant Therapy; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radioisotopes; Receptors, Peptide; Statistics, Nonparametric; Treatment Outcome; Tumor Burden; Yttrium Radioisotopes	2012
Efficacy and safety of 90Y-DOTATATE therapy in neuroendocrine tumours. Endokrynologia Polska, 2011, Volume: 62, Issue:5 Topics: Adult; Aged; Carcinoma, Neuroendocrine; Female; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Statistics as Topic; Thyroid Neoplasms; Treatment Outcome; Yttrium Radioisotopes	2011
Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes. International journal of radiation oncology, biology, physics, 2012, Jul-01, Volume: 83, Issue:3 Topics: Abdominal Pain; Aged; Analysis of Variance; Diarrhea; Embolization, Therapeutic; Fatigue; Female; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Nausea; Neuroendocrine Tumors; Retrospective Studies; Survival Rate; Treatment Outcome; Vomiting; Weight Loss; Yttrium Radioisotopes	2012
Predictors of response to radio-embolization (TheraSphere®) treatment of neuroendocrine liver metastasis. HPB : the official journal of the International Hepato Pancreato Biliary Association, 2012, Volume: 14, Issue:1 Topics: Aged; Embolization, Therapeutic; Female; Follow-Up Studies; Hepatic Artery; Humans; Injections, Intra-Arterial; Liver Neoplasms; Male; Microspheres; Middle Aged; Neuroendocrine Tumors; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Time Factors; Tomography, X-Ray Computed; Yttrium Radioisotopes	2012
Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Apr-01, Volume: 30, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Kidney; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Odds Ratio; Organometallic Compounds; Radioisotopes; Somatostatin; Yttrium Radioisotopes	2012
Therapy: Neuroendocrine cancer--are two radionuclides better than one? Nature reviews. Endocrinology, 2012, May-01, Volume: 8, Issue:6 Topics: Humans; Lutetium; Neuroendocrine Tumors; Radioisotopes; Somatostatin; Survival Rate; Treatment Outcome; Yttrium Radioisotopes	2012
Peptide receptor radionuclide therapy for neuroendocrine tumors in Germany: first results of a multi-institutional cancer registry. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2013, Volume: 194 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Female; Humans; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Prospective Studies; Radioisotopes; Receptors, Somatostatin; Registries; Yttrium Radioisotopes	2013
Polish experience in Peptide receptor radionuclide therapy. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2013, Volume: 194 Topics: Humans; Lutetium; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radioisotopes; Radiopharmaceuticals; Receptors, Somatostatin; Yttrium Radioisotopes	2013
90Y Radioembolization after radiation exposure from peptide receptor radionuclide therapy. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2012, Volume: 53, Issue:11 Topics: Analysis of Variance; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Receptors, Peptide; Retrospective Studies; Salvage Therapy; Yttrium Radioisotopes	2012
[Radionuclide therapy for cancer--what's new?]. Duodecim; laaketieteellinen aikakauskirja, 2012, Volume: 128, Issue:21 Topics: Embolization, Therapeutic; Female; Finland; Humans; Iodine Radioisotopes; Liver Neoplasms; Male; Neoplasms; Neuroendocrine Tumors; Octreotide; Paraganglioma; Pheochromocytoma; Prostatic Neoplasms; Radiotherapy; Thyroid Neoplasms; Yttrium Radioisotopes	2012
Patient-specific whole-body attenuation correction maps from a CT system for conjugate-view-based activity quantification: method development and evaluation. Cancer biotherapy & radiopharmaceuticals, 2012, Volume: 27, Issue:10 Topics: Female; Humans; Indium Radioisotopes; Iodine Radioisotopes; Lymphoma, B-Cell; Male; Neuroendocrine Tumors; Photons; Precision Medicine; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy Planning, Computer-Assisted; Scintillation Counting; Tomography, X-Ray Computed; Whole Body Imaging; Whole-Body Counting; Yttrium Radioisotopes	2012
Study of the impact of tissue density heterogeneities on 3-dimensional abdominal dosimetry: comparison between dose kernel convolution and direct Monte Carlo methods. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2013, Volume: 54, Issue:2 Topics: Antibodies, Monoclonal; Carcinoma, Hepatocellular; Humans; Imaging, Three-Dimensional; Iodine Radioisotopes; Liver Neoplasms; Lutetium; Lymphoma, Non-Hodgkin; Microspheres; Models, Statistical; Monte Carlo Method; Neuroendocrine Tumors; Radioisotopes; Radiometry; Radionuclide Imaging; Radiotherapy Dosage; Yttrium Radioisotopes	2013
Pre-therapeutic dosimetry with radiolabelled somatostatin analogues in patients with advanced neuroendocrine tumours. European journal of nuclear medicine and molecular imaging, 2005, Volume: 32, Issue:4 Topics: Body Burden; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neuroendocrine Tumors; Octreotide; Organ Specificity; Radiation Injuries; Radiation Protection; Radiometry; Radionuclide Imaging; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Relative Biological Effectiveness; Risk Assessment; Risk Factors; Somatostatin; Tissue Distribution; Yttrium Radioisotopes	2005
Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2006, Volume: 47, Issue:4 Topics: 3-Iodobenzylguanidine; Drug Therapy, Combination; Humans; Iodine Radioisotopes; Models, Biological; Neuroendocrine Tumors; Octreotide; Radiation Dosage; Radiopharmaceuticals; Yttrium Radioisotopes	2006
Gastroduodenal injury after radioembolization of hepatic tumors. The American journal of gastroenterology, 2007, Volume: 102, Issue:6 Topics: Animals; Carcinoma, Papillary; Carcinoma, Renal Cell; Collateral Circulation; Duodenum; Embolization, Therapeutic; Female; Hepatic Artery; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Neuroendocrine Tumors; Retrospective Studies; Stomach; Yttrium Radioisotopes	2007
DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy. European journal of nuclear medicine, 1997, Volume: 24, Issue:7 Topics: Abdominal Neoplasms; Adult; Humans; Indium Radioisotopes; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pentetic Acid; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Sensitivity and Specificity; Yttrium Radioisotopes	1997
Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet (London, England), 1998, Feb-07, Volume: 351, Issue:9100 Topics: Adult; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Receptors, Somatostatin; Yttrium Radioisotopes	1998
Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1999, Volume: 40, Issue:5 Topics: Adult; Aged; Female; Humans; Indium Radioisotopes; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Radiation Dosage; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Tissue Distribution; Yttrium Radioisotopes	1999
[Yttrium 90 DOTATOC: a new somatostatin analog for cancer therapy of neuroendocrine tumors]. Praxis, 1999, Aug-15, Volume: 88, Issue:31-32 Topics: Female; Follow-Up Studies; Humans; Middle Aged; Neuroendocrine Tumors; Octreotide; Pilot Projects; Prospective Studies; Radiation Injuries; Radionuclide Imaging; Radiotherapy Dosage; Receptors, Somatostatin; Treatment Outcome; Yttrium Radioisotopes	1999
Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues. The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), 1999, Volume: 43, Issue:4 Topics: Animals; Dose-Response Relationship, Radiation; Humans; Indium Radioisotopes; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Rats; Rats, Inbred Lew; Yttrium Radioisotopes	1999
Exceptional results in neuroendocrine-metastases-caused paraplegia treated with [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC), a radiolabelled somatostatin analogue. Clinical oncology (Royal College of Radiologists (Great Britain)), 2000, Volume: 12, Issue:2 Topics: Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Paraplegia; Radiopharmaceuticals; Somatostatin; Spinal Cord Compression; Spinal Neoplasms; Thoracic Vertebrae; Yttrium Radioisotopes	2000
Is (90)Y-DOTATOC treatment for neuroendocrine tumours safe? Medical science monitor : international medical journal of experimental and clinical research, 2002, Volume: 8, Issue:4 Topics: Animals; Antineoplastic Agents, Hormonal; Carcinoma, Medullary; Humans; Hypertension, Renal; Kidney Failure, Chronic; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Receptors, Somatostatin; Thyroid Neoplasms; Yttrium Radioisotopes	2002
Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2002, Volume: 43, Issue:5 Topics: Carcinoid Tumor; Humans; Middle Aged; Neuroendocrine Tumors; Octreotide; Pain, Intractable; Radionuclide Imaging; Radiopharmaceuticals; Yttrium Radioisotopes	2002
New advances in peptide receptor radionuclide therapy. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2002, Volume: 43, Issue:5 Topics: Humans; Kidney; Neuroendocrine Tumors; Octreotide; Radiopharmaceuticals; Yttrium Radioisotopes	2002